1650g - a pluripotent, allogeneic, tumor cell vaccine composed of irradiated tumor cells from the non-small cell lung cancer (nsclc) cell line 1650 and the immunoadjuvant recombinant granulocyte-macrophage colony stimulating factor (gm-csf) (1650-g), with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic cellular vaccine 1650-g may stimulate the immune system to exert a cytotoxic t-lymphocyte (ctl) immune response against tumor-associated antigens (taas) expressed on nsclc cells. Gm-csf potentiates the antitumor immune response. The 1650 cell line is used as a source for taas. Also see allogeneic cellular vaccine 1650-g
Up to date info
Latest research - 1650g
Source: Data courtesy of the U.S. National Library of Medicine. Since the data might have changed, please query MeSH on 1650g for any updates.